• Our CiPA Instruments

    HESI FDA BAA study: "Assessing variability and reproducibility of manual and automated patch clamp platforms"

  • CiPA hERG Protocol

    This protocol was used for hERG studies on the Patchliner and SyncroPatch 384PE.

  • HTS CiPA hERG Assay

    Effects of Cisapride using the CiPA hERG protocol on the SyncroPatch 384PE

  • Myocyte & Ion Channel Effects

    Arrhythmic Field potentials in iPSC-derived Cardiomyocytes (CardioExcyte 96) and hERG current inhibition (SyncroPatch 384PE)

  • Gigaseal HTS patch clamp

    CiPA-specified cardiac ion channels recorded at high throughput

  • Gigaseal HTS patch clamp

    High throughput recordings of cardiac ion channels at physiological temperature

  • CardioExcyte 96 screening tool

    CardioExcyte 96 with integrated liquid handling for cardiac safety screening

2020 - Unattended Screening Workflow in a 384-well Automated Patch Clamp System

 icon sp96   SyncroPatch 384i (a predecessor model of SyncroPatch 384) poster, Safety Pharmacology Society Virtual Meeting 2020   logo pdf   (2.6 MB)


Within ion channel working group efforts (Fermini et al., 2015), reference compounds were tested across multiple sites and automated patch clamp (APC) platforms (Kramer et al., 2020). Resulting IC50 values were variable between drugs and platforms. In general, as Iversen et al. (2012) outlined, the quality of an assay is defined by the robustness and reproducibility of the measurement signal in the absence of any test compounds. Data robustness and reliability using an APC instrumentation should be proven carefully before an unattended full-day screening workflow is implemented.

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.